Ikena Oncology, Inc is a Boston-based biopharmaceutical company that is revolutionizing targeted oncology treatments. With a focus on developing therapies that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network, Ikena aims to provide effective solutions for patients with high unmet needs.
Driven by scientific curiosity and a dedication to patients, Ikena is committed to developing differentiated therapies using the right modality for the right patient. With an ever-growing depth of institutional knowledge and a diverse pipeline of novel biomarker-driven targeted cancer therapies, Ikena is at the forefront of redefining the landscape of targeted oncology.
Generated from the website